×
News Home

Is it Time to Dump Zai Lab Ltd - ADR (ZLAB) Stock After it Is Down 10.31% in a Week?

Friday, January 14, 2022 03:42 PM | InvestorsObserver Analysts
Is it Time to Dump Zai Lab Ltd - ADR (ZLAB) Stock After it Is Down 10.31% in a Week?

The market has been neutral on Zai Lab Ltd - ADR (ZLAB) stock recently. ZLAB gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Zai Lab Ltd - ADR has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ZLAB!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ZLAB Stock Today?

Zai Lab Ltd - ADR (ZLAB) stock is trading at $49.40 as of 3:41 PM on Friday, Jan 14, a decline of -$2.24, or -4.34% from the previous closing price of $51.64. The stock has traded between $48.15 and $51.96 so far today. Volume today is less active than usual. So far 380,416 shares have traded compared to average volume of 665,801 shares.

More About Zai Lab Ltd - ADR

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. The company operates through the segment being Developing and commercializing proprietary therapeutics. Click Here to get the full Stock Report for Zai Lab Ltd - ADR stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App